Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 19/20 | 0.57 |
| ▸ | JAK1 known ✓ | P23458 | 18/20 | 0.57 |
| ▸ | JAK3 known ✓ | P52333 | 7/20 | 0.57 |
| ▸ | TYK2 known ✓ | P29597 | 3/20 | 0.57 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.49 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | LTK | P29376 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.49 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29080511 | 0.95 | JAK2 (0.53) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL101258 | 0.89 | JAK2 (0.55) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL101257 | 0.89 | JAK2 (0.55) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL13774673 | 0.89 | JAK2 (0.55) | JAK2JAK1JAK3TYK2RET | |
| Trifluoroacetic Acid SCHEMBL99863 | 0.86 | JAK2 (0.49) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL101692 | 0.83 | JAK2 (0.57) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL30663312 | 0.83 | JAK2 (0.57) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL101693 | 0.83 | JAK2 (0.57) | JAK2JAK1JAK3TYK2RET | |
| Phosphoric Acid SCHEMBL28725937 | 0.81 | JAK2 (0.55) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL101170 | 0.81 | JAK2 (0.56) | JAK2JAK1JAK3TYK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | claimed |
| CN-118159272-A | Treatment of alopecia disorders with deuterated JAK inhibitors | 太阳医药工业公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118159271-A | Treatment of JAK inhibition responsive conditions with prodrugs of JAK inhibitors | 太阳医药工业公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240166654-A1 | RUXOLITINIB CRYSTAL AND PHARMACEUTICAL COMPOSITION THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-117964625-A | Preparation method of high-optical-purity ponatinib intermediate | 安徽万邦医药科技股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117320725-A | Use of Pelabresib for treating anemia | 星座制药公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116348467-A | Methods for preparing enantiomerically enriched JAK inhibitors | 康塞特医药品有限公司 | 2023-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166654-A1 | RUXOLITINIB CRYSTAL AND PHARMACEUTICAL COMPOSITION THEREOF | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.